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To the Editor:
Chronic lymphocytic leukemia (CLL) remains incurable for
most patients, requiring repeated therapy [1]. The tetra-
spanin CD37 is predominantly expressed on mature B cells,
with low-level expression on T cells, granulocytes, and
monocytes, and is widely expressed in mature B-cell
malignancies, including CLL [2]. Upon cross-ligation,
CD37 can function as a cell death receptor in CLL cells [3].
Thus, CD37 is an attractive target for CLL.
BI 836826 is a chimeric mouse–human monoclonal
antibody that targets human CD37 with a dual mode of
action that induces antibody-dependent cell-mediated
cytotoxicity and has intrinsic proapoptotic activity [4]. BI
836826 has demonstrated stringent antitumor effects in
preclinical cell-based assays and xenograft models, with
superior activity versus rituximab [4]. These data warrant
evaluation of BI 836826 in CLL and other mature B-cell
malignancies. Here, we report a phase 1 ﬁrst-in-human,
open-label, dose-escalation study to evaluate the maximum
tolerated dose (MTD), safety and efﬁcacy of BI 836826 in
relapsed/refractory CLL (NCT01296932).
Eligible patients had relapsed/refractory CLL according
to the International Workshop on Chronic Lymphocytic
Leukemia (IWCLL) deﬁnition [5], and had received ≥2
prior treatment regimens (Supplementary Patients and
Methods). The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines, and the protocol approved by the relevant institutional
review boards. Patients provided written informed consent.
BI 836826 was administered at a starting dose of 1 mg
(Supplementary Patients and Methods; Suppl. Fig. 1). Dose
escalation followed a modiﬁed 3+ 3 design based on
protocol-deﬁned dose-limiting toxicities (DLTs; Supple-
mentary Materials and Methods) during the ﬁrst treatment
cycle. Primary endpoints were MTD and number of patients
with DLTs during cycle 1. MTD was deﬁned as the highest
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dose of BI 836826 for which the incidence of DLT was no
more than 1/6 patients during cycle 1. Patients received up
to four treatment cycles, with additional cycles permitted in
the case of clinical beneﬁt. An expansion cohort was
planned but did not occur because the trial was terminated
due to the lack of recruitment after new drugs (idelelisib/
ibrutinib) received marketing approval.
Adverse events (AEs) were graded according to the NCI-
CTCAE (National Cancer Institute-Common Terminology
Criteria for Adverse Events) (version 4.0) and collected up
to 42 days after the last dose of BI 836826 (on-treatment
period). Efﬁcacy endpoints included (amongst others): best
percentage change in peripheral lymphocyte count from
baseline; number of patients with improved hemoglobin
levels, platelet counts and neutrophil counts (Supplemen-
tary Patients and Methods); and best overall response by
investigator assessment according to IWCLL criteria [5].
Blood samples for pharmacokinetic analysis were taken
pre dose and at prespeciﬁed timepoints post dose
(Supplementary Patients and Methods). Pharmacodynamic
assessments were undertaken centrally and included
assessment of circulating B lymphocyte antigen (CD19+)
and CD19+/CD37+ cell counts (Supplementary Patients
and Methods). Statistical analyses were descriptive and
exploratory; no formal statistical tests were performed.
Primary endpoints were based on the MTD evaluable set;
the treated set was used for all other analyses.
Forty-ﬁve patients were screened across ten sites in three
countries from November 2011 to October 2015. Thirty-
seven patients were treated in eight cohorts: 1 mg (n= 3),
3 mg (n= 3), 9 mg (n= 6), 25 mg (n= 6), 50 mg (n= 3),
100 mg (n= 3), 200 mg (n= 6), 400 mg (n= 3), and
800 mg (n= 4). Median age (range) was 68 (44–80) years,
70% were male, and 65% had a del(17p) and/or TP53
mutation (Suppl. Table 1). Patients received a median of 7
cycles (range 1–68); 13 patients (35.1%) received 8 cycles
and ﬁve (13.5%) received >8 cycles. At the time of primary
analysis, 36 patients had discontinued treatment due to:
progressive disease (n= 10), DLT (n= 2), patient refusal
(n= 5), other AE (n= 7), or other reasons (n= 12). Two
patients (400 mg; 9 mg escalating to 25 mg after 16 cycles)
derived prolonged clinical beneﬁt and remained on treat-
ment for nearly 3 years (70 and 68 cycles, respectively).
Two of 35 evaluable patients experienced a DLT in cycle
1; grade 3 hypophosphatemia (200 mg cohort) and grade 4
neutropenia lasting >7 days (800 mg cohort; Suppl.
Table 2). Based on on-treatment DLTs and AEs leading to
discontinuation, 800 mg was not considered tolerable. No
DLTs were observed in patients receiving 400 mg. Doses
between 400 and 800 mg were not explored as the trial was
discontinued. A posthoc Bayesian logistic regression model
indicated that 600 mg might be acceptable for further
development.
Thirty-ﬁve patients (94.6%) had ≥1 treatment-related AE
(Table 1); the most frequent were infusion-related reactions
(IRRs), chills, and pyrexia. The most frequent treatment-
related grade 3/4 AEs were neutropenia, thrombocytopenia,
anemia, and leukopenia. Twelve patients (32.4%) had
treatment-related serious AEs, most frequently neutropenia
(8.1%), IRRs, pyrexia, and leukopenia (all 5.4%). There
were no cases of drug-related tumor lysis syndrome. Ten
patients (27.0%) had AEs that resulted in discontinuation of
BI 836826. AEs that most frequently resulted in dis-
continuation were thrombocytopenia and IRRs (both 5.4%).
There were no fatal on-treatment AEs. IRRs were observed
at all dose levels, most frequently in cycle 1 (Suppl. Fig. 2).
IRRs generally occurred during infusion and quickly
responded to standard management including treatment
interruption and symptomatic therapy. IRRs decreased in
frequency and severity following introduction of a mod-
iﬁed, stepwise, infusion scheme (Supplementary Patients
and Methods).
Table 1 Overall summary of AEs, and treatment-related AEs
occurring in >10% of patients
Any grade
n (%)
Grade 3 or 4
n (%)
Any AE 37 (100) 31 (83.8)
Treatment-related AE 35 (94.6) 27 (73.0)
Any SAE 18 (48.6) 13 (35.1)
Treatment-related SAE 12 (32.4) 8 (21.6)
AE leading to treatment
discontinuation
10 (27.0) 7 (18.9)
Most common treatment-
related AEs
Infusion-related reaction 26 (70.3) 3 (8.1)
Chills 22 (59.5) 0 (0.0)
Pyrexia 18 (48.6) 1 (2.7)
Neutropenia 17 (45.9) 16 (43.2)
Thrombocytopenia 12 (32.4) 9 (24.3)
Anemia 10 (27.0) 6 (16.2)
Dyspnea 8 (21.6) 2 (5.4)
Nausea 8 (21.6) 0 (0.0)
Leukopenia 7 (18.9) 6 (16.2)
Hypertension 5 (13.5) 2 (5.4)
Vomiting 5 (13.5) 0 (0.0)
Aspartate aminotransferase
increased
5 (13.5) 0 (0.0)
C-reactive protein increased 5 (13.5) 0 (0.0)
Alanine aminotransferase
increased
4 (10.8) 1 (2.7)
Hypotension 4 (10.8) 1 (2.7)
Asthenia 4 (10.8) 0 (0.0)
Hyperhidrosis 4 (10.8) 0 (0.0)
AE adverse event, SAE serious adverse event
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Baseline neutrophil, hemoglobin, and platelet counts were
low in 21.6%, 35.1%, and 51.4% of patients, respectively
(Table 1). During treatment, at least one neutrophil, hemo-
globin, or platelet measurement declined to <0.5 × 109/L
(grade 4), <80 g/L (grade 3), or <25 × 109/L (grade 4) in
62.1%, 43.2%, or 29.7% of patients, respectively. The degree
of preexisting cytopenia in these patients is shown in Suppl.
Fig. 3. Neutrophil and platelet counts declined immediately
after the end of the infusion, with recovery prior to the next
dose in most patients (Suppl. Fig. 4). Fifteen (40.5%) patients
had grade 4 neutropenia lasting ≥7 days; none had con-
comitant CTCAE grade ≥3 infections. Five patients (13.5%)
had grade 4 thrombocytopenia lasting ≥7 days; none had
concomitant bleeding events of CTCAE grade ≥3.
Clinically relevant reductions in lymphocyte count were
observed in all dose cohorts ≥9mg (Fig. 1), including patients
with a del(17p) or TP53 mutation. Improvements in hemo-
globin, neutrophil, and platelet counts are summarized in the
Supplementary results. Thirteen patients had an objective
response (35.1%; all PRs). At doses ≥9mg and ≥200mg,
objective response rates (ORRs) were 41.9% (13/31 patients)
and 61.5% (8/13 patients), respectively. ORR in patients with
a del(17p) mutation and/or a TP53 mutation was 45.8%
(11/24 patients). ORR in rituximab-refractory patients was
47.6% (10/21 patients). All evaluable patients achieved dis-
ease control (complete response, PR, or stable disease).
Plasma exposure was highly variable and increased more
than dose proportionally (Suppl. Table 3). No accumulation
of plasma concentrations was observed after repeated
administration. Following the end of infusions, plasma
concentrations decreased rapidly and were below the limit
of quantiﬁcation by 336 h for doses <400 mg. Plasma
clearance decreased with increasing doses, suggesting
target-mediated drug clearance. Also, the volume of dis-
tribution decreased with increasing doses, with moderate
variability across all dose groups.
At screening, CD37 expression on B cells was observed
in all 35 evaluable patients. The median percentage of
CD19+/CD37+ B cells was 86.4 (range 12.7‒95.3; stan-
dard deviation: 21.3). A change in peripheral CD19+ B
cells was seen at ≥9 mg, with a reduction following the ﬁrst
infusion. A clinically relevant and sustained reduction
became evident from doses approximately ≥100 mg (Suppl.
Fig. 5).
These data represent the ﬁrst human experience with BI
836826, and indicate that it is tolerable up to at least 400
mg; additional doses of 400–800 mg remain unexplored
due to study termination. The AE proﬁle was similar to
other Fc-modiﬁed antibodies [6–8], consisting pre-
dominantly of IRRs, neutropenia, and thrombocytopenia,
which were manageable with supportive care. The fre-
quency of IRRs and those resulting in treatment dis-
continuation were similar to those observed with other
antibodies such as obinutuzumab and XmAb5574 in
patients with CLL and were observed despite pre-
medication [7, 8]. IRRs with BI 836826 are not con-
sidered a barrier to further development, and may be
reduced by combination strategies that debulk CLL
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Fig. 1 Best percentage change from baseline in peripheral blood
lymphocyte count by patient. a Patients presented with del(17p) and/or
TP53 mutation. b Patients had a baseline lymphocyte count of <4 ×
109/L. c Patients had a best percentage change from baseline to a
lymphocyte count of <4 × 109/L. d Patient was randomized to 200 mg
but was escalated to 400 mg. e Patient was randomized to 9 mg but
was escalated to 25 mg. f Patient was randomized to 800 mg but was
de-escalated to 600 mg in cycle 3 and received 800 mg again by error
in cycle 4. g Patients received only the predose, i.e., the ﬁrst part of the
split infusion of BI 836826 in cycle 1, which was 10% of the total
dose, but maximally 10 mg
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burden prior to initial infusion. Neutropenia and throm-
bocytopenia were not associated with severe infections or
bleeding. Their rapid kinetics and recovery suggest that
cytopenia may be related to direct effects of BI 836826 on
mature peripheral blood cells, as supported by preclinical
data (unpublished). Prolonged administration of BI
836826 was possible without cumulative toxicity, with
two patients receiving almost 3 years of treatment.
BI 836826 demonstrated notable clinical activity,
achieving a clearance of CLL cells from peripheral blood.
At doses that showed the strongest pharmacodynamic effect
on B-lymphocyte counts, the ORR was 61.5%. Responses
were also observed in patients with del(17p) or TP53
mutations. Although phase 1/2 studies are limited by small
patient numbers and dose variations, response rates with BI
836826 compare favorably to otlertuzumab or rituximab as
single agents in CLL [9, 10], and are in the range observed
with ofatumumab and obinutuzumab [6, 11]. Moreover,
there is preclinical rationale to use BI 836826 in combina-
tion with cytotoxics and nonchemotherapy agents such as
idelalisib [12, 13].
Overall, this study indicates that BI 836826 treatment in
patients with CLL is a valid approach with acceptable tol-
erability and notable efﬁcacy, especially in difﬁcult-to-treat
patients with poor-risk features including del(17p) or TP53
mutations. CD37 is a promising therapeutic target that
warrants further clinical investigation in CLL.
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To the Editor:
The clinical relevance of measurable residual disease
(MRD) monitoring has been well recognized in acute
myeloid leukemia (AML) [1] and respective assays have
been established for several recurrent leukemic markers
[2, 3]. However, although internal tandem duplications in
the FLT3 gene (FLT3-ITDs) are the most common poor
prognosis AML drivers [4], they have remained a challen-
ging target: Their heterogeneity makes conventional PCR-
based methods either insensitive or laborious [5]. Yet with
recently approved FLT3-kinase inhibitors available [6], a
speciﬁc monitoring of FLT3-mutation loads, and thus
response to targeted therapy, is of particular interest. Next-
generation sequencing (NGS) workﬂows for FLT3-ITD
monitoring have been described, but were previously either
proprietary or undisclosed [7, 8], unable to detect and cor-
rectly annotate all of the tested ITDs [9, 10], or used in
conjunction with manual analysis with inherently subjective
results [10].
We have therefore developed a new method based
on targeted high-coverage NGS and our novel, open-
source analysis program getITD. For assay assessment,
we sequenced 3 human AML cell lines (Leibniz
Institute DSMZ-German Collection of Microorganisms
and Cell Cultures, Braunschweig, Germany), 2 healthy
volunteers, and 57 samples from 28 AML patients who
were all included in the AMLSG BiO Registry study
(NCT01252485) and gave their informed consent according
to the Declaration of Helsinki. We show that our workﬂow
detects ITDs of a broad range of lengths, insertion sites and
variant allele frequencies (VAFs) with high accuracy and
precision, is fully objective without any requirement for
manual analysis, and thus applicable to routine clinical
monitoring. Sample and method details are provided
as supplementary information. getITD is freely available at
https://github.com/tjblaette/getitd.
To demonstrate our assay’s speciﬁcity, we analyzed three
FLT3-ITD negative control samples (peripheral blood of
healthy volunteers, n= 2; AML cell line HL-60). No ITDs
were reported, indicating an assay speciﬁcity of 100%
(coverage: 1.1–4.2 million, mean 2.6 million paired-end
reads). To assess sensitivity, we analyzed two serial dilu-
tions of FLT3-ITD positive in FLT3-ITD-negative DNA
from AML cell lines MOLM-14 (21 bp ITD, 67% VAF
[11]), PL-21 (126 bp ITD, 33% VAF [11]), and HL-60
(FLT3-ITD negative [11]). For each of the ITD-positive cell
lines, we sequenced undiluted DNA and 3–4 serial 1:10
dilutions in HL-60 (1.1–2.9 million, mean 2.0 million
paired-end reads). The expected ITDs were detected in all
samples and VAF estimates were accurate and decreased
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